None listed
Conditions
Interventions
None listed
Sponsors
Cheil General Hospital & Women's healthcare center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with hypertension who are 20 years old and higher and need angiotensin ? receptor blockers(ARBs), Fimasartan(Kanarb) 2.Patients who agreed to this study and handed out written consent forms 3.Patients who visited after fasting
Exclusion criteria
Exclusion criteria: 1. Patients who are currently taking Kanarb
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the frequency and incidence of major adverse cardiovascular event(MACE) in the treated kanarb during average 3 years of follow-up visits using a cohort study with office hypertension | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in degree of metabolic risk after 3 months of follow-up observation.;A incidence of metabolic syndrome and diabetes after 1-year follow-up ;Effect of blood pressure changes and side effects according to presence or absence of metabolic syndrome;Difference of clinic and home blood pressure after Kanarb treatment;changes of incidence of white coat and masked hypertension after Kanarb treatment;Changes of blood pressure variability after Kanarb treatment | — |
Countries
Korea, Republic of
Contacts
Public ContactSuk Jeong
Cheil General Hospital & Women's healthcare center
Outcome results
None listed